A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Post-Conference Report Provides HIV Cure Roadmap
Life Expectancy With HIV Increases Dramatically
Improper Use of a Neti Pot Can Be Fatal
Animal Studies Suggest Anti-Reservoir Drugs May Help 'Functionally Cure' HIV
Tenofovir Microbicide Gel Falters in Major HIV Prevention Study
Gold Drug Shows HIV Eradication Potential
New Studies Under Way of Sangamo's Possible 'Functional Cure' Gene Therapy
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

November 13, 2008

Treatment Interruptions May Still Have a Future

Temporarily stopping antiretroviral (ARV) therapy may turn out to be safe and advantageous in some circumstances, according to two studies presented at the Ninth International Congress on Drug Therapy in HIV Infection held in Glasgow and reported by AIDSmap.

Results from the Strategic Management of Antiretroviral Therapy (SMART) study have largely put the kibosh on the idea of HIV treatment breaks. The largest treatment interruption study conducted to date, SMART compared people who remained on continuous ARV therapy with people who either delayed or stopped treatment until their CD4 counts fell below 250 cells. In January 2006, the 5,500-patient study was stopped early because of more side effects, health complications and deaths among people who delayed or stopped treatment.

Data from the smaller LOTTI study, reported in Glasgow by Franco Maggiolo, MD, from the Ospital Riuniti in Bergamo, Italy, paint a more optimistic picture. In this clinical trial, where 329 HIV-positive people stopped and restarted treatment at higher CD4 counts than in SMART—700 cells and 350 cells, respectively—the rate of deaths and complications was similar among those who interrupted therapy and those who remained on continuous treatment.

The primary outcomes measured in the study were deaths, progression to AIDS or hospitalization for any reason. After an average of four years in the study, Dr. Maggiolo reported, 12 percent of those who took treatment breaks and 11 percent of those who remained on therapy reached one of these outcomes. People in the drug holiday group were able to remain off treatment 65 percent of the time, and people whose lowest-ever CD4 count was 500 were able to remain off treatment 85 percent of the time.

In direct contrast with SMART, there were actually 10 times as many cardiovascular and metabolic complications in the continuous therapy group in LOTTI than in the treatment break group. Maggiolo pointed to several possible explanations for the contradictory results. First, only 5 percent of patients in the LOTTI study ever had CD4 counts below 350 compared with 35 percent in SMART. Second, because SMART was stopped early, it may not have had enough time for cardiovascular and metabolic events to occur in the continuous treatment group.

A second treatment interruption study, presented by Cal Cohen, MD, from Harvard Medical School in Boston, tried a completely different approach. Called the FOTO study, for “Five On, Two Off,” this trial compared 42 people who stopped taking their meds for two days every weekend with people who remained on continuous therapy. All the patients took Sustiva (efavirenz) plus Truvada (tenofovir plus emtricitabine).

After 24 weeks, 83 percent of those who took treatment breaks had viral loads under 50 compared with 80 percent of those who remained on continuous treatment. Excluding study drop-outs—most left due to the intensive monitoring involved—100 percent of those who took treatment breaks had viral loads under 50, compared with 85 percent in the continuous treatment arm.

While there are still more data to be analyzed from LOTTI and FOTO, the authors of both studies suggest that treatment breaks may still have a future in HIV treatment, despite the results of SMART. This could be good news for people with HIV, who in the FOTO study overwhelmingly liked the option of taking a drug holiday every weekend.

Search: treatment interruption, break, drug holiday, SMART, LOTTI, FOTO, Franco Maggiolo, Cal Cohen, Sustiva, efavirenz, Truvada, tenofovir, emtricitabine


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

thomas bruneau, new orleans la, 2008-11-19 11:40:28
i was very sick in sept. stopped everything because of a serious GI infection even IV meds where comming up but i have sence been back to my reg meds and my counts only dropped slighty and now im back on them my counts are back to where then belong i was off my hiv meds 34 days and only back on them 30 days and im back to normal. feelin good

oshipshiyo, Onalaska, 2008-11-19 11:17:21
I have been on contious treatment sence I was diagonesed in Nov. of 1999 I have changed drugs in March of 2002, because I found that my privous treatment was eating muscle tissue & I lift weights to get my body bigger. My DR put me on ATRIPLA & my viral load is 819.

comments 1 - 2 (of 2 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    jeri33415
    west palm beach
    Florida


    Muzungu
    Granada Hills, SFV
    California


    sexyboy3086
    orange county
    California


    jeffinga
    atlanta
    Georgia
Click here to join POZ Personals!
Conference Coverage

6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


XVIII International AIDS Conference
Vienna, Austria
July 18-23, 2010

more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.